Streetbeat News

Earnings

ADN

AIM

AIRS

BFRI

BLIN

CAAS

CEPU

CWCO

ITRM

KITT

LGVN

MBRX

NEO

NYC

RGF

RWLK

SGBX

SHCO

SPB

STRR

TSAT

TUSK

VISL

Several companies are scheduled to report their earnings on August 11, 2023. Some of these include Consolidated Water Co, Associated Cap Gr, Longeveron, Star Equity Hldgs, The Real Good Food, Iterum Therapeutics, Advent Technologies Hldgs, ReWalk Robotics, Soho House, Nauticus Robotics, Moleculin Biotech, Biofrontera, AirSculpt Technologies, Spectrum Brands Holdings, China Automotive Systems, Telesat, NeoGenomics, Vislink Technologies, American Strategic, AIM ImmunoTech, Mammoth Energy Services, Antero Resources, Bridgeline Digital, Safe & Green Holdings, and Central Puerto.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 11:05 am

ASLN

ASLAN Pharma (NASDAQ:ASLN) reported Q2 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.80) by 86.25%. This is an 88.42% increase over losses from the same period last year. The company also reported $12.00 million in sales this quarter.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:04 am

ITRM

Iterum Therapeutics reported Q2 cash, cash equivalents and short-term investments of $44.7M. This is expected to provide a cash runway into Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:04 am

AVAL

BENF

BLND

CANO

KODK

MAXN

MKFG

PGEN

SENS

VLD

Several stocks recorded losses in Friday's pre-market trading session. Cano Health, Maxeon Solar Technologies, Markforged Holding Corporation, Grupo Aval Acciones y Valores, Velo3D, Blend Labs, Senseonics Holdings, Eastman Kodak Company, Beneficient, and Precigen all saw their shares fall. The declines were largely due to worse-than-expected Q2 financial results and lower-than-expected revenue guidance.

Portfolio Pulse from Lisa Levin

August 11, 2023 | 11:03 am

ITRM

Iterum Therapeutics reported Q2 losses of $(0.77) per share, beating the analyst consensus estimate of $(0.80) by 3.75%. However, this represents a 63.83% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:02 am

BFRI

Biofrontera reported Q2 losses of $(7.23) per share, missing the analyst consensus estimate of $(5.14) by 40.66%. This is a 50.63% decrease over losses from the same period last year. The company also reported quarterly sales of $5.85 million, missing the analyst consensus estimate of $5.86 million by 0.20%. However, this is a 31.21% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:01 am

MBRX

Moleculin Biotech reported Q2 losses of $(0.20) per share, beating the analyst consensus estimate of $(0.28) by 28.57%. This is a 16.67% increase over losses from the same period last year. The company had cash and cash equivalents of $32.2 million as of June 30, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 10:51 am

SPB

Spectrum Brands (SPB) anticipates that some of the short-term demand headwinds will persist into Q4.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 10:34 am

SPB

Spectrum Brands has maintained its FY23 earnings framework but expects net sales to decline by mid single-digits. Excluding investment income, the company anticipates its adjusted EBITDA to be down low to mid single-digits.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 10:33 am

SPB

Spectrum Brands Holdings (NYSE:SPB) reported Q3 adjusted earnings of $0.75 per share, beating the analyst consensus estimate of $0.57 by 31.58%. However, the company's quarterly sales of $735.50 million missed the analyst consensus estimate of $780.97 million by 5.82%. This represents a 10.09% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 10:30 am